Project Details:

Analogue-based Drug Discovery Vol. III

Project No.:2011-011-1-700
Start date:2011-06-01
End date:2013-03-01
Division:Chemistry and Human Health Division
Objective:

The project “Analogue-based Drug Discovery II” has been successfully completed within two years and the second volume of the book series has been published by Wiley-VCH. The good resonance of both Vol. I and Vol. II. justifies a continuation of the book series with a third volume to be published in 2012.

Description:

proposed content:

General Aspects

Lead and Drug Optimizations (Fischer, Richter, Hungary)

Physicochemical Parameters (Ulander, AstraZeneca, Sweden)

Metabolic Stability and Optimization of Drug Analogues (Vastag, Richter, Hungary) P

rocess Chemistry Driven Synthesis of New Analogues (Chorghade, IUPAC)

Drug Classes

Epigenetic Drugs (Ganesan, University of East Anglia, Norwick, UK)

P2Y12 Receptor Inhibitors (Jakubowski, Lilly, USA)

SERM Drugs (Erhardt, Uni. of Toledo, USA)

Insulin Analogues (Sridhar, Endocrine and Diabetes Centre, India)

Case Studies

Dabigatran (Priebke, Boehringer Ingelheim, Germany)

Escitalopram (Bøgesø, Lundbeck, Denmark)

Tapentadol (Buschmann, Grünenthal, Germany)

Ulimorelin (Peterson, Tranzyme, USA)

Asenapine (Gilfillan, Merck, USA)

Cabazitaxel (Vrignaud, Bouchard, Sanofi Aventis, France)

Boceprevir (Prongay, Venkatraman; Merck, USA)

Progress:

Project completed - the book edited by Janos Fischer, C. Robin Ganellin, and David P. Rotella has been published by Wiley-VCH, 2013, ISBN: 978-3-527-33073-7

A overview is published in Chem Int Jan 2013

Last update 15 April 2013

 

Chairman: